ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

The agreement announced Monday gives GSK access to a platform technology developed by ABL Bio. Specific diseases covered by the pact were not disclosed. The deal kicks off with GSK paying South ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, ...

As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume ...

South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...

(RTTNews) - ABL Bio Inc. announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier or BBB shuttle ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...